Vistagen targets NDA submission for fasedienol in mid-2026 as PALISADE-3 study nears data ...

Q2 2026 Management View President and CEO Shawn Singh announced "another major milestone in our PALISADE program. The last patient completed the randomized double-blind portion of our PALISADE-3 Phase ...